Medical-device maker Boston Scientific (NYSE:BSX) yesterday released data from a clinical trial showing that its Promus Element drug-eluting stent showed advantages over Abbott's (NYSE: ABT) Xience V drug-eluting stent with less blood vessel straightening over a three-year period.
The Promus Element also demonstrated less unplanned or emergency stenting as compared with the Xience V, in line with earlier data, along with a lower rate of inadequate lesion coverage, among other advantages. Separate data showed less vessel straightening with the Promus Element, which can lead to improved blood flow, according to Boston Scientific.
The FDA first approved the Promus Element Plus Stent System in 2011; Boston Scientific's system earlier picked up CE Mark approval in 2009.
Fool contributor Dan Carroll and The Motley Fool have no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
The Online Grocery Market Is Amazon's to Lose
Amazon's online grocery sales doubled its next closest competitor in 2017.
Social Security's 3 Purposes, and the 1 Thing It Was Never Intended For
America's most important social program is tasked with providing a financial backdrop for tens of millions of Americans.
3 Key Metrics for Duluth Holdings Investors to Watch
With most of the company’s growth tied to expanding retail sales, here are a few simple ways to measure its progress.